Ocugen Agrees to Sell OCU400 Rights in Australia, New Zealand and the ASEAN Region

John Kim

1 min read

Ocugen Agrees to Sell OCU400 Rights in Australia, New Zealand and the ASEAN Region

The agreement would give Australian biopharma Celairis Therapeutics exclusive commercialization rights to the gene therapy candidate in those areas.

By John Kim

Published Nov 11, 2026, 11:20 AM EST

Gloved hands examine a clear vial under bright laboratory lights / TokenPost.ai

Ocugen agreed to sell Celairis Therapeutics exclusive commercialization rights to OCU400 in Australia, New Zealand and the ASEAN region. The agreement would give the Australian biopharma rights to the gene therapy candidate across those areas.

Ocugen and Celairis announced the agreement Tuesday, Nov. 10.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.